VERACYTE INC (VCYT)

July 19th Options Now Available For Veracyte (VCYT)

Veracyte to Participate in Upcoming Investor Conferences

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Veracyte (NASDAQ:VCYT) just reported results for the first quarter of 2024.Vera...

Veracyte Announces First Quarter 2024 Financial Results

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Veracyte Becomes Oversold (VCYT)

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Commit To Buy Veracyte At $12.50, Earn 16% Annualized Using Options

Veracyte files automatic mixed securities shelf (NASDAQ:VCYT)

Veracyte (VCYT) announces mixed shelf offering in latest prospectus; not an invitation to sell securities.

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Veracyte GAAP EPS of -$0.39 misses by $0.30, revenue of $98.2M beats by $5.42M (NASDAQ:VCYT)

Veracyte, a medical diagnostics company, reports Q4 2023 financial results with missed EPS but beats revenue expectations.

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Veracyte Completes Acquisition of C2i Genomics

Veracyte Q4 revenue to grow by 18%-20% Y/Y (NASDAQ:VCYT)

Veracyte's Q4 revenue should be between $95M and $96M, an increase of between 18% and 20% from last year.

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Veracyte GAAP EPS of -$0.41 misses by $0.26, revenue of $90.1M beats by $5.71M (NASDAQ:VCYT)

Veracyte reported Q3 financial results, with a GAAP EPS miss of $0.26 and a revenue beat of $5.71M.

Veracyte Announces Third Quarter 2023 Financial Results

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

VCYT Makes Bullish Cross Above Critical Moving Average